Key result
MicroNET-covered CGuard stent lacks quantitative twelve-month outcomes for carotid revascularization.
Why the study?
In carotid artery stenting with conventional stents, most 30-day adverse neurologic events occur post-procedurally, largely due to plaque prolapse and cerebral embolism not eliminated by classic closed-cell designs.
Does a MicroNET-covered embolic prevention stent improve outcomes in patients undergoing carotid revascularisation?
Observational
Does a MicroNET-covered embolic prevention stent improve outcomes in patients undergoing carotid revascularisation?
Missing 12-month quantitative data in the abstract precludes outcome assessment; leaves open long-term efficacy of MicroNET-covered CGuard stents in carotid revascularization.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mazurek et al. (2020) conducted an observational in Carotid revascularisation. MicroNET-covered embolic prevention stent CGuard was evaluated. The truncated abstract does not provide quantitative twelve-month outcomes for the MicroNET-covered CGuard stent in patients undergoing carotid revascularization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: